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Edited by Masayuki MiyasakaAbstract We have used bee venom phospholipase A2 as a vector
to load human dendritic cells ex vivo with a major histocompat-
ibility complex (MHC) class I-restricted epitope fused to its C-
terminus. The fusion protein bound to human monocyte-derived
dendritic cells and was internalized into early endosomes. In vitro
immunization experiments showed that these dendritic cells were
able to generate speciﬁc CD8 T cell lines against the epitope car-
ried by the fusion protein. Cross-presentation did not require
proteasome, transporter associated with antigen processing, or
endosome proteases, but required newly synthesized MHC mol-
ecules. Comparison of the antigen presentation pathway ob-
served in this study to that followed by other toxins used as
vectors is discussed.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Many studies have shown the extraordinary potential of den-
dritic cells (DCs) prepared ex vivo for anti-cancer or anti-viral
immunotherapy [1,2]. DCs loaded with tumor or viral antigens
are able to present major histocompatibility complex (MHC)
class I and class II peptide epitopes to CD8 and CD4 T lympho-
cytes, generating an immune response against these antigens.
Many ways of loading DCs with antigens exist, but no method
is ideal and each has its own advantages and drawbacks. The
use of antigenic peptide epitopes or lipopeptides is limited by
MHC restriction, a given peptide being immunogenic in a lim-
ited set of individuals. Fusion of tumor cells with DCs [3], incu-
bation with cell lysates [4], apoptotic bodies [5], heat shock
protein-associated tumor proteins [6] and tumor messenger
RNA transfection [7] provide poorly characterized antigensAbbreviations: APCs, antigen presenting cells; BFA, brefeldin A; bv-
PLA2, bee venom phospholipase A2; CMV, cytomegalovirus; DCs,
dendritic cells; MHC, major histocompatibility complex; PBMCs, p-
eripheral blood mononuclear cells; TAP, transporter associated with
antigen processing; Tf, transferrin; uP30–34, unfolded P30–34
*Corresponding author. Fax: +33 1 69 08 94 30.
E-mail address: daniel.gillet@cea.fr (D. Gillet).
0014-5793/$30.00  2005 Federation of European Biochemical Societies. Pu
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such as viruses or large bacterial toxins for the delivery of anti-
gen DNA or protein into DCs may lead to competition between
epitopes from the vector and the antigen for presentation, and
to a strong immune response against the vector, precluding fur-
ther vaccination with that vector. Moreover, viral vectors still
face safety and regulatory problems [9,10].
This work describes a new vector to deliver protein antigens
to DCs, enabling eﬃcient cross-presentation of MHC class I-
restricted epitopes. It is based on the use of bee venom phos-
pholipase A2 (bvPLA2) as a cell membrane-binding vector
for antigens fused to its C-terminus. bvPLA2 is a small protein
of 15 kDa, which binds tightly to phospholipid membranes to
gain access to its phospholipid substrate [11]. Although
bvPLA2 is not very toxic to cells, the mutation H34Q in the
catalytic site abolishes enzymatic activity and toxicity without
aﬀecting membrane binding [12]. We have fused model HLA-
A2 restricted epitopes from the lower matrix 65 kDa phospho-
protein (pp65) of the cytomegalovirus (CMV) [13,14] to the
C-terminus of the H34Q mutant of bvPLA2 (bvPLA2-
H34Q). We have studied the binding of this fusion protein to
human DCs, its internalization, and the cross-presentation of
the CMV-derived epitopes it contained to CD8 T cells.2. Materials and methods
2.1. Culture medium, cytokines, reagents, peptides and cell lines
IMDM (Gibco Invitrogen, Cergy Pontoise, France) was supple-
mented with 10% human AB serum (Biowest, AbCys, Paris, France),
0.24 mM aspartate, 0.55 mM arginine, 1.5 mM glutamine (Sigma,
St. Quentin Fallavier, France) and 1% v/v penicillin–streptomycin
(Gibco Invitrogen). Cytokines were from R&D (Lille, France), except
IL-15, which was from Peprotech (Rocky Hill, NJ). Human albumin
was from LFB (Courtaboeuf, France). Clasto-lactacystin b-lactone,
chloroquine and brefeldin A (BFA) were from Sigma. Conjugates
for ﬂow cytometry were from BD Biosciences (Pont de Claix, France).
Peptides N9V and M9V were from Neosystem (Strasbourg, France).
The recombinant US6 protein was the kind gift of Dr. Tampe´ and
Dr. Kyritsis (Institute of Physiological Chemistry, Marburg, Ger-
many) [15]. Oligonucleotides were from Eurobio (Les Ulis, France).
Cell lines T1 and T2 were obtained from the ATCC (Manassas,
VA). T3 cells were kindly provided by Dr. Arnaud Morris (Pasteur
Institute, Paris, France).
2.2. Fusion protein
The expression plasmid for the fusion protein P30–34 was derived
from plasmid pQE-WT PLA2 [16]. A BamHI restriction site was intro-
duced after the last codon of the bvPLA2 sequence to introduce a syn-blished by Elsevier B.V. All rights reserved.
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and followed by the three amino acids found in the native sequence
of pp65. A His-tag and a kallikrein cleavage site were present at the
bvPLA2 N-terminus. In summary, the native sequence of bvPLA2
was preceded by the sequence MRGSHHHHHHGSPFR and followed
by the sequence GSLARNLVPMVATVQGQPLKMLNIPSINVH-
HYGS (epitopes in bold letters). The H34Q mutation was then intro-
duced by site-directed mutagenesis in the bvPLA2 sequence. The entire
coding region of the construct was sequenced. Expression of the pro-
tein in Escherichia coli, extraction of the inclusion bodies, His-tag med-
iated puriﬁcation and in vitro refolding were done as described in [17]
with a ﬁnal yield of 2 mg of protein per liter of culture. The unfolded
form of P30–34 (uP30–34) was sulfonated on its cysteines to prevent
folding and aggregation [17]. For FACS and confocal microscopy
experiments, P30–34 was labeled with Alexa488 carboxylic acid succin-
imidyl ester using the A-10235 labeling kit (Molecular Probes, Eugene,
OR) according to the manufacturers protocol.
2.3. Generation of DCs from monocytes
Human DCs were generated as described in [18,19]. In some exper-
iments, DCs were generated from adherent monocyte precursors cul-
tured in the presence of IL-4 and GM-CSF. Results obtained with
both types of DCs were equivalent. DCs were typed by ﬂow cytometry
for the following markers: CD1a, CD14, CD16, CD80, CD83, CD86,
MHC I, MHC II. HLA-A2 typing of the healthy donors peripheral
blood mononuclear cells (PBMCs) was done using monoclonal anti-
body BB7.2 (BD Bioscience).
2.4. Internalization assay using confocal microscopy
DCs were washed twice with phosphate-buﬀered saline (PBS) and
spread onto poly L-lysine coated coverslips. Cells were allowed to ad-
here 20 min at room temperature in PBS, before recovering for 40 min
at 37 C in complete medium. Cells were washed once with PBS and
incubated with 3 lM of P30–34-Alexa488 in PBS for 1 h at room tem-
perature. They were then washed with RPMI supplemented with 2%
fetal bovine serum, then incubated for 1 h in the same medium supple-
mented with 1 mg/ml dextran–rhodamine (66 kDa), 100 nM transfer-
rin-Cy5 (Tf-Cy5) or 100 nM baﬁlomycin A1, as indicated. Cells were
washed, then ﬁxed with 3.7% paraformaldehyde. For immunoﬂuores-
cence detection of Lamp-1, they were permeabilized with 0.1% saponin
in PBS containing 0.1% bovine serum albumin and incubated with an
anti-Lamp-1 monoclonal antibody (DSHB, University of Iowa), and
then with rhodamine-labeled goat anti-mouse antibodies (Sigma). Cells
were ﬁnally mounted in Moviol and examined under a Leica TCS 4D
confocal microscope as described in [20]. Medial optical sections were
recorded using a 63· objective. Fluorescence levels were equilibrated
so that crosstalks between channels were negligible.Fig. 1. (A) Near-UV circular dichroism spectra of bvPLA2 from
venom (thin line), recombinant bvPLA2 (middle line) and P30–34
(thick line). Inset, far-UV (from 195 to 250 nm) circular dichroism
spectra of bvPLA2 from venom and recombinant bvPLA2 (overlap-2.5. Generation of antigen-speciﬁc CD8 T cell lines
CD8 T cells were puriﬁed from non-adherent PBMCs by negative
selection using the CD8 T cell Isolation Kit (Miltenyi Biotec, Paris,
France) and were characterized by ﬂow cytometry. Unless stated
otherwise, immature DCs were pulsed for 1.5 h at 37 C in PBS with
3 lM P30–34 or uP30–34 or 3 lM peptide N9V and 5 lg/ml human
b2-microglobulin, and washed. CD8 T cells (1.5 · 105/well) were co-
cultured with autologous antigen-pulsed DCs (3 · 104/well) in 96-well
U-bottom plates in Iscove medium supplemented with 1000 U/ml
IL-6, 5 ng/ml IL-12, 500 U/ml IFNc and 1 lg/ml bacterial extract
for maturation (Ribomunyl, Pierre Fabre Medicament, Boulogne,
France) [19]. On day 7, DCs pulsed in the same conditions were used
to re-stimulate the T cells in the presence of 20 U/ml IL-2, 10 ng/ml IL-
7, 1 lg/ml bacterial extract and 500 U/ml IFNc. On day 14, T cells
were re-stimulated with pulsed DCs in the presence of 25 ng/ml IL-7,
25 ng/ml IL-15, 500 U/ml IFNc and 1 lg/ml bacterial extract.ping on the upper trace) and P30–34 (lower trace). (B–D) FACS
analysis of P30–34 binding to DCs. (B) DCs were incubated with 3 lM
of the indicated proteins for 1.5 h. DCs were then incubated with a
rabbit anti-bvPLA2 serum and with a phycoerythrin anti-rabbit IgG
antibody. The dotted line corresponds to control DCs incubated only
with the serum and the labeled antibody and the dashed line to DCs
only. (C) DCs were incubated with the indicated concentration of P30–
34-Alexa488 for 1.5 h in PBS at 37 C. (D) DCs were incubated with 3
lM of P30–34-Alexa488 for the indicated time in PBS at 37 C. The
dashed line corresponds to unlabeled DCs.2.6. Stimulation of CD8 T cell lines by APCs loaded with antigens
Stimulation experiments of established speciﬁc CD8 T cell lines by
antigen presenting cells (APCs) loaded with antigens were performed
by conventional IFNc ELISPOT assay [21]. APCs (DCs or T1, T2
or T3 cells) (104/well) pulsed with the antigen were mixed with CD8
T cells (103/well). Controls included APCs alone and T cells in presence
of APCs and 10 lg/ml phytohemaglutinin. IFNc ELISPOT assays
were done after overnight incubation at 37 C. Spots were countedwith an AID ELISPOT reader (Straßberg, Germany). For experiments
with inhibitors, DCs were treated with the inhibitor during the antigen
pulse, washed and cultured with the same doses of inhibitor for 5 h to
allow eventual processing prior to incubation with the T cells in the
ELISPOT plates. When treated with chloroquine, NH4Cl, leupeptine
and BFA, DCs were ﬁxed with glutaraldehyde before incubation with
the T cells because the eﬀect of these drugs is reversible.3. Results
3.1. Recombinant protein P30–34
A recombinant protein (referred to as P30–34 thereafter)
was produced in which the immuno-dominant epitope
NLVPMVATV (N9V) [13,14] and the sub-dominant epitope
MLNIPSINV (M9V) of pp65 from CMV [13] were fused to
the C-terminus of bvPLA2-H34Q. These epitopes correspond,
respectively, to positions 495–503 and 120–128 of pp65. Both
are HLA-A2-restricted. Each epitope sequence was preceded
and followed by the three amino acids found in the native se-
quence of pp65 (see Section 2). These extra residues were in-
cluded to favor proper processing.
The protein structure was analyzed by circular dichroism in
the far- and near-UV. Spectra were compared to those ob-
tained with recombinant bvPLA2 and bvPLA2 puriﬁed from
venom (Fig. 1A). The spectra in the far-UV revealed that
P30–34 contained secondary structures similar to those of
the natural bvPLA2 plus some additional random structures,
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epitope sequence at the C-terminus of the protein. The spectra
in the near-UV were very similar for the three proteins, indicat-
ing the presence of a native-like tertiary structure for the
bvPLA2 part of P30–34.
We also produced an uP30–34 by sulfonation of its cysteines
to prevent folding and aggregation. It was recognized on a
Western blot by a polyclonal rabbit serum against bvPLA2
(not shown) and was expected to be unable to bind to cell
membranes.
3.2. Binding and internalization of P30–34 by DCs
Binding of P30–34 and uP30–34 to DCs was evaluated by
ﬂow cytometry. Binding was analyzed for both forms of the
protein using a polyclonal rabbit serum against bvPLA2 and
a phycoerythrin-anti-rabbit secondary antibody. P30–34
bound to DCs was detected by the antibodies while no binding
of uP30–34 to DCs was found (Fig. 1B). This conﬁrmed that
binding of P30–34 to the membrane of DCs was dependant
on proper folding of the protein. To determine the best binding
conditions, P30–34 was labeled with the ﬂuorescent probe
Alexa488 and incubated with the cells in PBS for various
lengths of time and concentrations. Figs. 1C and D show that
maximal binding was reached after 1.5 h for a P30–34 concen-
tration of 3 lM. Higher protein concentrations or longer incu-
bation times did not signiﬁcantly increase binding.
We studied the internalization of P30–34 by DCs using con-
focal microscopy. Cells were ﬁrst exposed to P30–34-Alexa488
at 20 C before incubation for 1 h at 37 C with Tf-Cy5 to label
early endosomes, and with 66 kDa dextran-rhodamine, a tra-
cer endocytosed by ﬂuid phase uptake and directed to endo-
somes and then lysosomes [22]. As shown in Fig. 2, DCsFig. 2. Internalization of P30–34 by DCs. Upper panel, DCs loaded with P30
dextran-rhodamine (red). Lower panels, DCs loaded with P30–34-Alexa488 (
absence of baﬁlomycin (Baf). Lamp-1 was revealed by immuno-ﬂuorescence (
Scale bars = 10 lm.eﬃciently internalized P30–34. Dextran extensively colocalized
with Tf (60%) indicating that in the absence of chase a large
fraction of dextran remained in early endosomes. Accumula-
tion of P30–34 could be observed within these early endosomes
(Tf+ and dextran+ structures) and to some extent within late
endosomes (Tf and dextran+ structures) (Fig. 2). Delivery
of P30–34 to late endocytic elements was conﬁrmed using the
late endosome/lysosome marker Lamp-1 [22]. Endocytosed
P30–34 was found within Lamp-1 positive structures (Fig. 2)
and P30–34 transport to lysosomes was inhibited in the pres-
ence of baﬁlomycin, which neutralizes endosomes [22]. This
ﬁnding is in agreement with previous studies showing that
baﬁlomycin blocks cargo delivery to lysosomes [23].
Taken together, these data indicate that P30–34 was able to
bind to the surface of DCs and was then eﬃciently internalized
within early endosomes and routed toward late endosomes/
lysosomes during the ﬁrst hour following exposure of DCs.
3.3. Generation of speciﬁc CD8 T cell lines against epitopes N9V
and M9V by DCs loaded with protein P30–34
In order to study the capacity of human DCs to present epi-
topes contained in the P30–34 protein, we performed in vitro
immunization experiments. Puriﬁed HLA-A2 CD8 T cells
from healthy donors were stimulated with autologous DCs
loaded with P30–34. The uP30–34 as well as synthetic 9-mer
peptides N9V and M9V were used as controls. In particular,
uP30–34 was used to determine whether binding of P30–34 en-
hanced epitope presentation. DCs were incubated with the
proteins or the peptides at a concentration of 3 lM in PBS
for 1.5 h and then mixed with the CD8 T cells in 96-well plates.
After three such stimulations over three weeks, the cell content
of each well was assayed for speciﬁcity against peptides N9V–34-Alexa488 (green) and then incubated for 1 h with Tf-Cy5 (blue) and
green) and then incubated for 1 h with Tf-Cy5 (blue) in the presence or
red). Medial optical sections were obtained with a confocal microscope.
Table 1
Eﬃciency of generation of N9V-speciﬁc CD8 T cell lines using P30–34,
uP30–34, or N9V as antigens in in vitro immunizations
Healthy donor # N9V-speciﬁc cell lines/number of seeded wells
Generated
with P30–34
Generated
with uP30–34
Generated
with N9V
HD 04 13/20 (65%) 18/20 (90%)
HD 15 4/20 (20%) 1/20 (5%) 10/20 (50%)
HD 29 20/20 (100%) 9/20 (45%) 20/20 (100%)
HD 33 24/30 (80%) 27/30 (90%)
Total 61/90 (68%) 10/40 (25%) 75/90 (83%)
Speciﬁcity was assessed using DCs loaded with peptide N9V.
Fig. 4. Eﬀect of the concentration of peptide N9V or protein P30–34
used for the loading of DCs on the response of N9V-speciﬁc CD8 T
cell lines. The level of stimulation was monitored by IFNc ELISPOT.
Unloaded DCs were used as controls.
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N9V or M9V). When DCs were loaded with P30–34, 68% of
seeded wells contained T cell lines speciﬁc for N9V (Table 1).
In contrast, when DCs were loaded with uP30–34, only 25%
of wells contained T cell lines speciﬁc for N9V. In control
experiments with DCs loaded with peptide N9V, 83% of
seeded wells contained T cell lines speciﬁc for N9V. Very few
cell lines were generated against epitope M9V, whether DCs
were loaded with P30–34 or peptide M9V. This may be ex-
plained by the subdominance of M9V [13], while N9V is dom-
inant. Therefore, we focused the study on the N9V epitope
only.
Together, the results show that a dominant epitope linked to
bvPLA2-H34Q can be eﬃciently presented to circulating CD8
T cells by DCs. Also, the results strongly suggest that binding
of the vector protein to the surface of DCs enhance presenta-
tion of the epitope it carries.
3.4. Activation of CD8 T cell lines speciﬁc for epitope N9V by
DCs loaded with protein P30–34
We studied the capacity of DCs loaded with P30–34 to
activate N9V-speciﬁc T cell lines established in the previous
experiment (T cell lines generated by DCs loaded with either
P30–34, uP30–34 or peptide N9V). As controls, we used DCs
loaded with uP30–34, bvPLA2, peptide N9V, peptide M9V
or PBS alone. All T cell lines were activated by DCs loaded
with P30–34 (Fig. 3). They all responded to peptide N9V as
well. In sharp contrast, T cells did not respond to DCs incu-
bated with uP30–34. As expected, they did not respond toFig. 3. Response proﬁle of N9V-speciﬁc CD8 T cell lines generated
with DCs loaded with either peptide N9V, proteins P30–34 or uP30–
34. Cell lines were named after healthy donor # (HD#) and the antigen
used for their generation (N for peptide N9V, P for P30–34 and uP for
uP30–34). After screening of T cell lines for N9V-speciﬁcity, their
response against PBS, peptides N9V or M9V and proteins P30–34,
uP30–34 or bvPLA2 was monitored by IFNc ELISPOT (see bar motif
correspondence on the ﬁgure). Peptides and proteins were incubated
with DCs at a concentration of 3 lM.bvPLA2 or peptide M9V either. These results further assess
the speciﬁcity of the N9V-speciﬁc T cell lines and do not reveal
any diﬀerence in speciﬁcity among cell lines generated with the
peptide or the protein carrying the N9V epitope. These data
also show that DCs do not eﬃciently present the epitope car-
ried by uP30–34. This conﬁrms that P30–34 must bind to the
surface of DCs for the epitope to be eﬃciently presented.
To get a rough estimate of the eﬃciency of epitope genera-
tion using the P30–34 protein, we compared the stimulation
of N9V-speciﬁc cell lines by DCs incubated with decreasing
doses of protein or peptide. The results in Fig. 4 show that pre-
sentation of epitope N9V required 100-fold more protein than
peptide, suggesting that roughly 1 epitope was produced and
presented from 100 protein copies. Maximum stimulation
was reached when DCs were incubated with P30–34 at a con-
centration of 3 lM, the concentration giving maximum bind-
ing to the DCs.
3.5. Cross-presentation of epitope N9V from protein P30–34 did
not require proteasome nor TAP activities, was chloroquine
insensitive but BFA sensitive
In an attempt to analyze the processing pathway followed by
P30–34, we studied the role played by the proteasome, the
transporter associated with antigen processing (TAP), the
endosome acidity and the Golgi in the presentation of P30–34.
DCs were treated with clasto-lactacystin b-lactone, an irre-
versible inhibitor of proteasome function [24]. Ten lM of
inhibitor did not aﬀect presentation of epitope N9V carried by
P30–34 or as a free peptide (Fig. 5A). In contrast, clasto-
lactacystin b-lactone was able to inhibit by 63% the presenta-
tion of the intracellular tumor antigen NY-ESO-1 by
SK-MEL-37 tumor cells, but not of its epitope S9C as a peptide
incubated with the cells [25] (data not shown). These results
indicate that the protein P30–34 was not processed by the pro-
teasome of DCs for presentation of its N9V epitope to T cells.
The cell lines T1 and T2 were used as APCs to study the role
of TAP in the presentation of epitope N9V from P30–34. T1 is
a T cell-B cell hybridoma capable of cross-presentation. T2 is a
TAP-deﬁcient derivative of T1 generated by mutagenesis. T1
and T2 cells were incubated with the protein P30–34 or the
peptide N9V under the same conditions as DCs. T1 and T2
incubated with P30–34 had the same capacity to stimulate
N9V-speciﬁc T cells (Fig. 5B). Similar results were obtained
using the cell line T3 instead of T1, which was derived from
T2 by TAP reconstitution following gene transfer (Fig. 5C).
In another experiment, DCs were incubated with recombinant
US6 protein, a potent TAP inhibitor expressed by CMV [15]
Fig. 5. Role of proteasome, TAP, endosome acidiﬁcation and Golgi in
the presentation of P30–34. (A) DCs were treated with (squares) or
without (circles) 10 lM clasto-lactacystin b-lactone to block protea-
some during loading with the indicated concentrations of N9V (closed
symbols) or P30–34 (open symbols). Unloaded DCs treated with
(dash) or without (cross) 10 lM clasto-lactacystin b-lactone were used
as controls. (B) The cell lines T1 (squares) or T2 (circles) were used as
APCs and loaded with the indicated concentrations of N9V (closed
symbols) or P30–34 (open symbols). Unloaded T1 (cross) or T2 (dash)
were used as controls. (C) Same as B except that T3 cells (squares) were
used in place of T1. Unloaded T3 (cross) or T2 (dash) were used as
controls. (D) DCs were treated with the indicated concentrations of
US6 during loading with 3 lM of the indicated antigen. (E,F) DCs
were treated with the indicated concentrations of chloroquine or BFA
during loading with 3 lM (circles) or 0.3 lM (squares) of N9V (closed
symbols) or P30–34 (open symbols). Unloaded DCs were used as
controls (cross). In all panels, the level of stimulation was monitored
by IFNc ELISPOT. Each panel is named after the CD8 T cell line used
(see Fig. 3 legend).
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sentation of epitope N9V from P30–34 (Fig. 5D). Altogether,
these results indicate that cross-presentation of the N9V epi-
tope processed from P30–34 was not dependent on TAP func-
tion. As expected, presentation of the peptide N9V used as acontrol, which binds directly to HLA-A2 at the surface of
the presenting cells without need for processing, was not
dependent on TAP.
In order to study the role of endosomal proteases in the pro-
cessing of N9V contained in the P30–34 protein, DCs were
treated with chloroquine (Fig. 5E) or NH4Cl (not shown),
which are inhibitors of endosome acidiﬁcation (and thus of
endosomal proteases) and with leupeptine (not shown), which
is an inhibitor of some endosomal proteases [26]. None of these
inhibitors aﬀected presentation of epitope N9V carried by
P30–34. As expected, presentation of the control peptide
N9V was not aﬀected either. These data indicate that process-
ing of P30–34 did not involve endosomal proteases.
The possibility that P30–34 was processed by extracellular
proteases once bound to the surface of DCs was investigated.
We compared the presentation of P30–34 by DCs alive or ﬁxed
with glutaraldehyde prior to incubation with the antigen. Glu-
taraldehyde blocks intracellular traﬃcking and thus intracellu-
lar processing, but not processing by extracellular proteases
[27]. Presentation of epitope N9V from P30–34 was strongly
decreased using ﬁxed DCs (66–78% decrease in presentation).
In contrast, presentation of peptide N9V was almost as eﬃ-
cient using ﬁxed or untreated DCs (17–21% decrease in presen-
tation). uP30–34 was not presented by DCs ﬁxed or untreated.
These results suggest that P30–34 was not processed by extra-
cellular proteases.
Finally, DCs were treated with BFA, a fungal metabolite
that disassemble the Golgi apparatus, blocking the transport
of neo-synthesized MHC class I molecules from the endoplas-
mic reticulum to the surface [26]. Two lg/ml of BFA com-
pletely abolished presentation of epitope N9V from P30–34,
but not of peptide N9V (Fig. 5F). The level of HLA-A2 on
the cell surface was moderately reduced (not shown). These re-
sults show that an intact, functional Golgi is required for
cross-presentation of epitope N9V from P30–34. Therefore,
they suggest that binding of the epitope to MHC class I mol-
ecules occurs in intracellular compartments involved in the
secretory pathway containing newly synthesized MHC mole-
cules and not in recycling vesicles.4. Discussion
We have shown that the mutant bvPLA2-H34Q can be used
as a membrane-binding vector for the attachment of epitopes
or antigens to the membrane of DCs ex vivo. The fusion pro-
tein P30–34, in which epitopes N9V and M9V were fused to
bvPLA2-H34Q, was internalized by the DCs into early endo-
somes and within 1 h reached the late endosomes/lysosomes.
One of the epitopes, N9V, which has been described as domi-
nant [13,14], was eﬃciently processed and presented to CD8 T
cells. DCs loaded with P30–34 were able both to generate eﬃ-
ciently N9V-speciﬁc T cell lines and to activate existing N9V-
speciﬁc cell lines. The membrane-binding activity of bvPLA2
played an essential role in the cross-presentation of the fusion
protein. Indeed, the uP30–34, unable to bind to DCs was less
eﬃcient to generate N9V-speciﬁc T cell lines and totally unable
to activate established N9V-speciﬁc T cells in IFNc ELISPOT
assays.
The cross-presentation of the epitope N9V from P30–34
was less eﬃcient than the presentation of the free peptide
N9V. This is explained by the direct availability of class I
A. Babon et al. / FEBS Letters 579 (2005) 1658–1664 1663molecules at the cell surface for peptide binding. Neverthe-
less, the results presented here show the potential of
bvPLA2-H34Q as a vector for loading protein antigens onto
DCs for presentation of their MHC class I epitopes to T
cells. This may have application for the design of vaccines
using DCs loaded ex vivo with tumor or viral antigens
[1,2]. Antigens as whole proteins are much better immuno-
gens than peptides because they contain a set of epitopes,
which usually encompass the polymorphism of MHC class
II and class I molecules. Thus, a protein vaccine may protect
more individuals than a vaccine containing a single peptide
epitope. However, soluble proteins are poorly internalized
by DCs, justifying the need for a vector. Preliminary data
with a bvPLA2-H34Q-tumor antigen fusion protein showed
the presentation of MHC class II and class I epitopes to
CD4 and CD8 T cells, respectively (unpublished results).
Another question raised by our study is the presentation path-
way followed by antigens vectorized by bvPLA2-H34Q. The
data presented here show that cross-presentation of P30–34 is
independent from proteasome, TAP or endosome proteases,
but requires a functional Golgi apparatus. Antigens captured
by DCs may follow diﬀerent routes of processing for their epi-
topes to be loaded onto MHC class I molecules and presented
to T cells [28]. In a ﬁrst pathway, internalized antigens are trans-
located from the phagosome to the cytoplasm where they are
chopped into peptides by the proteasome [29,30]. These peptides
are transported back into the phagosome by TAP where they
bind to newly synthesized MHC class I molecules. Peptide-
MHC class I complexes are then targeted to the cell surface.
In a second pathway, internalized antigens can be degraded into
peptides by proteases present inside the endosomes following
acidiﬁcation of these compartments [26,28]. These peptides
can then bind to preformed MHC class I molecules recycled
from the cell surface to the endosomes. However, antigens
loaded onto DCs using bacterial or plant toxins as vectors can
follow other routes of presentation. In particular, pertussis tox-
in, shiga toxin, Pseudomonas exotoxin A or ricin used as vectors
direct the antigen from early endosomes to the endoplasmic
reticulum using the retrograde transport through the Golgi
[31,32]. This route is independent from endosome acidiﬁcation
but is blocked by BFA [33]. Processing of antigens following this
pathway can be independent from proteasome, TAP or endo-
some proteases [31,32,34] but may rely on proteases inside the
reticulum such as signal peptidase [32] or endoplasmic reticulum
aminopeptidase associated with antigen processing (ERAAP)
[35]. Then, generated peptide epitopes bind to newly synthesized
MHC class I molecules en route to the surface through the Gol-
gi. Together, our data strongly suggest that P30–34 followed the
same processing and presentation pathway.
A last possibility would be that processing involved extracel-
lular proteases, the generated epitopes binding directly to cell
surface HLA-A2 molecules. If this was the case, the eﬀect of
BFA on the presentation of P30–34 should be due to a de-
crease of cell surface HLA-A2 and should aﬀect the presenta-
tion of peptide N9V as well. In contrast, the presentation of
peptide N9V was not aﬀected by BFA and the level of cell sur-
face HLA-A2 was only slightly reduced. In addition, P30–34
was not presented by DCs ﬁxed with glutaraldehyde, a treat-
ment known to block intracellular processing but not extracel-
lular processing [27], while the peptide was. uP30–34 was not
presented by ﬁxed or untreated DCs, showing also the absence
of extracellular processing.A recent work showed that the enzymatic activity of bvPLA2
induces the maturation of DCs [36]. Thus, the use of wild type
bvPLA2 instead of bvPLA2-H34Q as a vector may further in-
crease the eﬃciency of antigen presentation, a possibility which
remains to be tested. Overall, our data show that bvPLA2-
H34Q can function as a membrane-binding vector to attach
antigens to the membrane of DCs ex vivo, leading to recogni-
tion by and activation of CD8 T cell.
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